"Carcinoma, Renal Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
| Descriptor ID |
D002292
|
| MeSH Number(s) |
C04.557.470.200.025.390 C04.588.945.947.535.160 C12.758.820.750.160 C12.777.419.473.160 C13.351.937.820.535.160 C13.351.968.419.473.160
|
| Concept/Terms |
Carcinoma, Renal Cell- Carcinoma, Renal Cell
- Carcinomas, Renal Cell
- Renal Cell Carcinomas
- Adenocarcinoma, Renal Cell
- Adenocarcinomas, Renal Cell
- Renal Cell Adenocarcinoma
- Renal Cell Adenocarcinomas
- Adenocarcinoma Of Kidney
- Adenocarcinoma Of Kidneys
- Kidney, Adenocarcinoma Of
- Kidneys, Adenocarcinoma Of
- Renal Cell Cancer
- Cancer, Renal Cell
- Cancers, Renal Cell
- Renal Cell Cancers
- Adenocarcinoma, Renal
- Adenocarcinomas, Renal
- Renal Adenocarcinoma
- Renal Adenocarcinomas
- Nephroid Carcinoma
- Carcinoma, Nephroid
- Carcinomas, Nephroid
- Nephroid Carcinomas
- Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma- Clear Cell Renal Cell Carcinoma
- Grawitz Tumor
- Tumor, Grawitz
- Clear Cell Renal Carcinoma
- Carcinoma, Hypernephroid
- Carcinomas, Hypernephroid
- Hypernephroid Carcinoma
- Hypernephroid Carcinomas
- Hypernephroma
- Hypernephromas
Collecting Duct Carcinoma (Kidney)- Collecting Duct Carcinoma (Kidney)
- Carcinoma, Collecting Duct (Kidney)
- Carcinomas, Collecting Duct (Kidney)
- Collecting Duct Carcinomas (Kidney)
- Collecting Duct Carcinoma of the Kidney
- Renal Collecting Duct Carcinoma
- Collecting Duct Carcinoma
- Carcinoma, Collecting Duct
- Carcinomas, Collecting Duct
- Collecting Duct Carcinomas
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Renal Cell".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Renal Cell".
This graph shows the total number of publications written about "Carcinoma, Renal Cell" by people in this website by year, and whether "Carcinoma, Renal Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 10 | 2 | 12 |
| 1995 | 13 | 2 | 15 |
| 1996 | 13 | 1 | 14 |
| 1997 | 15 | 2 | 17 |
| 1998 | 11 | 1 | 12 |
| 1999 | 9 | 1 | 10 |
| 2000 | 5 | 5 | 10 |
| 2001 | 15 | 2 | 17 |
| 2002 | 22 | 4 | 26 |
| 2003 | 28 | 7 | 35 |
| 2004 | 20 | 2 | 22 |
| 2005 | 22 | 3 | 25 |
| 2006 | 29 | 3 | 32 |
| 2007 | 38 | 2 | 40 |
| 2008 | 43 | 7 | 50 |
| 2009 | 38 | 5 | 43 |
| 2010 | 51 | 5 | 56 |
| 2011 | 58 | 4 | 62 |
| 2012 | 47 | 4 | 51 |
| 2013 | 49 | 4 | 53 |
| 2014 | 62 | 7 | 69 |
| 2015 | 64 | 2 | 66 |
| 2016 | 42 | 5 | 47 |
| 2017 | 59 | 1 | 60 |
| 2018 | 42 | 2 | 44 |
| 2019 | 33 | 1 | 34 |
| 2020 | 43 | 4 | 47 |
| 2021 | 50 | 0 | 50 |
| 2022 | 29 | 1 | 30 |
| 2023 | 33 | 1 | 34 |
| 2024 | 28 | 4 | 32 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma, Renal Cell" by people in Profiles.
-
Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone. Cancer Res Commun. 2024 Oct 01; 4(10):2621-2637.
-
A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer. Cancer Res Commun. 2024 Sep 01; 4(9):2444-2453.
-
Therapeutic vaccine targeting dual immune checkpoints induces potent multifunctional CD8+ T cell anti-tumor immunity. Int Immunopharmacol. 2024 Dec 05; 142(Pt A):113004.
-
Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series. RMD Open. 2024 Aug 30; 10(3).
-
Mitochondrial complex I promotes kidney cancer metastasis. Nature. 2024 Sep; 633(8031):923-931.
-
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Ann Oncol. 2024 Nov; 35(11):1026-1038.
-
Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024 Aug 01; 7(8):e2425288.
-
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214. J Immunother Cancer. 2024 Jul 25; 12(7).
-
Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma. BJU Int. 2024 Oct; 134(4):596-601.
-
Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma. Oncologist. 2024 Jul 05; 29(7):589-595.